Clinical Trial Update: Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on navtemadlin (KRT-232) with or without anti-PD-1/PD-L1 for Merkel cell carcinoma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• KRT-232
• Navtemadlin (navtemadlin)

Snippet

Sponsor: Kartos Therapeutics, Inc. | Conditions: Merkel Cell Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN